Franklin Genomic Advancements ETF (HELX)
| Assets | $20.93M |
| Expense Ratio | 0.50% |
| PE Ratio | 28.35 |
| Shares Out | 650,000 |
| Dividend (ttm) | $0.14 |
| Dividend Yield | 0.45% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | 12.43% |
| Volume | 93 |
| Open | 31.68 |
| Previous Close | 32.37 |
| Day's Range | 31.68 - 31.68 |
| 52-Week Low | 23.74 |
| 52-Week High | 38.17 |
| Beta | 1.10 |
| Holdings | 65 |
| Inception Date | Feb 25, 2020 |
About HELX
Fund Home PageThe Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.
Top 10 Holdings
44.79% of assets| Name | Symbol | Weight |
|---|---|---|
| Natera, Inc. | NTRA | 6.88% |
| Guardant Health, Inc. | GH | 6.66% |
| Krystal Biotech, Inc. | KRYS | 5.42% |
| United Therapeutics Corporation | UTHR | 4.21% |
| BridgeBio Pharma, Inc. | BBIO | 4.06% |
| Insmed Incorporated | INSM | 4.06% |
| Ligand Pharmaceuticals Incorporated | LGND | 3.80% |
| Samsung Biologics Co.,Ltd. | 207940 | 3.28% |
| AstraZeneca PLC | AZN | 3.23% |
| Cash | n/a | 3.18% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.14334 | Jan 8, 2026 |
| Dec 30, 2021 | $0.00394 | Jan 7, 2022 |
| Dec 13, 2021 | $0.11415 | Dec 21, 2021 |
| Dec 14, 2020 | $0.05178 | Dec 23, 2020 |
Performance
HELX had a total return of 11.56% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.75%.
News
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...